ImmunoGen Undervalued In AbbVie Deal, Shareholder Claims
By Elaine Briseño · January 8, 2024, 4:57 PM EST
A shareholder alleges that ImmunoGen Inc. directors and advisers significantly undervalued the company while preparing to sell to AbbVie Inc., including by failing to consider the $1.6 billion in projected revenue...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login